Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial

Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial

BackgroundIrritable bowel syndrome (IBS) is a common functional gastrointestinal disorder in adults. Systematic reviews with meta-analyses have demonstrated the efficacy and safety of probiotics in improving symptoms of IBS.AimThe aim of the study was to demonstrate the efficacy and safety of Limosi...

Full description

Bibliographic Details
Main Authors: Silvia Cruchet, Sandra Hirsch, Diana Villa-López, Mucio Moreno-Portillo, Juan C. Palomo, Ana T. Abreu-Abreu, Juan M. Abdo-Francis, Carlos Jiménez-Gutiérrez, Martin Rojano, Gabriel López-Velázquez, Pedro Gutiérrez-Castrellón
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Gastroenterology
Subjects:
L. reuteri DSM 17938
L. reuteri ATCC PTA 6475
irritable bowel syndrome
adults
randomized controlled (clinical) trial
Online Access:https://www.frontiersin.org/articles/10.3389/fgstr.2023.1296048/full

Internet

https://www.frontiersin.org/articles/10.3389/fgstr.2023.1296048/full

Similar Items